Gilboa Therapeutics is a preclinical-stage cancer immunotherapy company with a mission to dramatically improve outcomes and save lives.

The company is focused on the development of SolidT, a next-generation cell therapy designed to harness the power of a patients own immune system to treat a wide range of cancers.SolidT cells are designed to deliver a highly specific and potent attack that has demonstrated complete eradication of tumors in animal models while leaving healthy tissue unharmed.

Its innovative platform technology has the potential to benefit patients with a range of both solid and hematological tumors, with an improved safety profile compared to other cell therapy approaches.